Evidence map›Paper›PMID 41895280›Full record

ArticleCancer cell2026

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.

Chaitanya Bandlamudi, Daniel Muldoon, Ino de Bruijn, Mingxuan Zhang, Michael V Gormally, Emily C Harrold, Subhiksha Nandakumar, Shaleigh A Smith, Mark Y Jeng, Sydney Woods and 79 more

Erratum issuedAbstract read
In one paragraph

Article in Cancer cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

89 authors.

Chaitanya BandlamudiMarie-Josée and Henry R. Kravis Center for Molecular Oncology; Department of Pathology and Laboratory Medicine. Electronic address: bandlamc@mskcc.org.
Daniel MuldoonMarie-Josée and Henry R. Kravis Center for Molecular Oncology; Department of Pathology and Laboratory Medicine.
Ino de BruijnMarie-Josée and Henry R. Kravis Center for Molecular Oncology; Department of Epidemiology and Biostatistics.
Mingxuan ZhangDepartment of Epidemiology and Biostatistics.
Michael V GormallyDepartment of Medicine.
Emily C HarroldDepartment of Medicine.
Subhiksha NandakumarMarie-Josée and Henry R. Kravis Center for Molecular Oncology; Department of Epidemiology and Biostatistics.
Shaleigh A SmithDepartment of Epidemiology and Biostatistics.
Mark Y JengDepartment of Medicine.
Sydney WoodsDepartment of Pathology and Laboratory Medicine.
Kanika AroraMarie-Josée and Henry R. Kravis Center for Molecular Oncology; Department of Pathology and Laboratory Medicine.
Walid K ChatilaMarie-Josée and Henry R. Kravis Center for Molecular Oncology; Department of Epidemiology and Biostatistics.
Bastien NguyenDepartment of Epidemiology and Biostatistics.
Henry WalchDepartment of Epidemiology and Biostatistics.
Jun WooMarie-Josée and Henry R. Kravis Center for Molecular Oncology.
Craig M BielskiDepartment of Epidemiology and Biostatistics.
Christopher FongMarie-Josée and Henry R. Kravis Center for Molecular Oncology; Department of Epidemiology and Biostatistics.
Thinh N TranDepartment of Epidemiology and Biostatistics.
Gaofei ZhaoDepartment of Epidemiology and Biostatistics.
Miika MehineMarie-Josée and Henry R. Kravis Center for Molecular Oncology; Department of Pathology and Laboratory Medicine.
Maria A PerryMarie-Josée and Henry R. Kravis Center for Molecular Oncology; Department of Pathology and Laboratory Medicine.
Sam E TischfieldMarie-Josée and Henry R. Kravis Center for Molecular Oncology.
Allison L RichardsMarie-Josée and Henry R. Kravis Center for Molecular Oncology.
Suraj RajendranDepartment of Pathology and Laboratory Medicine.
Hongxin ZhangMarie-Josée and Henry R. Kravis Center for Molecular Oncology.
Christoph K KreitzerDepartment of Epidemiology and Biostatistics.
Ronak ShahMarie-Josée and Henry R. Kravis Center for Molecular Oncology.
Risha HuqMarie-Josée and Henry R. Kravis Center for Molecular Oncology.
Jesse GalleResearch and Technology Management.
Tina AlanoMarie-Josée and Henry R. Kravis Center for Molecular Oncology; Department of Nursing.
Ramyasree MadupuriMarie-Josée and Henry R. Kravis Center for Molecular Oncology.
Ritika KundraMarie-Josée and Henry R. Kravis Center for Molecular Oncology.
Justin JeeMarie-Josée and Henry R. Kravis Center for Molecular Oncology; Department of Epidemiology and Biostatistics; Department of Medicine.
Karl PichottaMarie-Josée and Henry R. Kravis Center for Molecular Oncology; Department of Epidemiology and Biostatistics.
Michele WatersMarie-Josée and Henry R. Kravis Center for Molecular Oncology; Department of Epidemiology and Biostatistics.
Richard A HickmanDepartment of Pathology and Laboratory Medicine.
Josephine K DermawanDepartment of Pathology and Laboratory Medicine.
Jie-Fu ChenDepartment of Pathology and Laboratory Medicine.
Anton SafonovDepartment of Medicine.
Konrad H StopsackDepartment of Medicine.
Ritesh R KotechaDepartment of Medicine.
Hira A RizviDepartment of Medicine.
Claire F FriedmanDepartment of Medicine.
Pedram RazaviDepartment of Medicine.
Ezra RosenDepartment of Medicine.
Yonina R Murciano-GoroffDepartment of Medicine.
Luc G T MorrisDepartment of Surgery.
James A FaginDepartment of Medicine; Human Oncology and Pathogenesis Program.
Ingo K MellinghoffDepartment of Neurology; Human Oncology and Pathogenesis Program.
Ping ChiDepartment of Medicine; Human Oncology and Pathogenesis Program.
Neerav N ShuklaDepartment of Pediatrics.
Adam J SchoenfeldDepartment of Medicine.
Gregory J RielyDepartment of Medicine.
Charles M RudinDepartment of Medicine.
Alexander DrilonDepartment of Medicine.
Jake June-Koo LeeDepartment of Epidemiology and Biostatistics; Department of Medicine.
Hikmat A Al-AhmadieDepartment of Pathology and Laboratory Medicine.
Gopa IyerDepartment of Medicine.
Anna M VargheseDepartment of Medicine.
Eileen M O'ReillyDepartment of Medicine.
Zsofia K StadlerDepartment of Medicine.
Mark E RobsonDepartment of Medicine.
Ed ReznikDepartment of Epidemiology and Biostatistics.
JianJiong GaoMarie-Josée and Henry R. Kravis Center for Molecular Oncology; Department of Epidemiology and Biostatistics.
Diana MandelkerDepartment of Pathology and Laboratory Medicine.
Irina OstrovnayaDepartment of Epidemiology and Biostatistics.
Satshil RanaDepartment of Pathology and Laboratory Medicine.
Gowtham JayakumaranDepartment of Pathology and Laboratory Medicine.
Anita BowmanDepartment of Pathology and Laboratory Medicine.
Abhinita MohantyDepartment of Pathology and Laboratory Medicine.
Anoop Rema BalakrishnanDepartment of Pathology and Laboratory Medicine.
Aijazuddin SyedDepartment of Pathology and Laboratory Medicine.
Ryan N PtashkinDepartment of Pathology and Laboratory Medicine.
Jacklyn Casanova-MurphyDepartment of Pathology and Laboratory Medicine.
Debyani ChakravartyDepartment of Pathology and Laboratory Medicine.
Ryma BenayedDepartment of Pathology and Laboratory Medicine.
Maria E ArcilaDepartment of Pathology and Laboratory Medicine.
Sarat ChandarlapatyDepartment of Medicine; Human Oncology and Pathogenesis Program.
Helena A YuDepartment of Medicine.
Neal RosenDepartment of Medicine; Human Oncology and Pathogenesis Program.
Mark T A DonoghueMarie-Josée and Henry R. Kravis Center for Molecular Oncology.
Christopher A KlebanoffDepartment of Medicine; Immuno-Oncology Program; Center for Cellular Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rona YaegerDepartment of Medicine.
A Rose BrannonDepartment of Pathology and Laboratory Medicine.
Ahmet ZehirDepartment of Pathology and Laboratory Medicine.
Marc LadanyiDepartment of Pathology and Laboratory Medicine; Human Oncology and Pathogenesis Program.
Nikolaus SchultzMarie-Josée and Henry R. Kravis Center for Molecular Oncology; Department of Epidemiology and Biostatistics; Human Oncology and Pathogenesis Program.
David B SolitMarie-Josée and Henry R. Kravis Center for Molecular Oncology; Department of Medicine; Human Oncology and Pathogenesis Program.
Michael F BergerMarie-Josée and Henry R. Kravis Center for Molecular Oncology; Department of Pathology and Laboratory Medicine; Human Oncology and Pathogenesis Program. Electronic address: bergerm1@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Total Neoadjuvant Therapy (TNT) for Borderline Resectable and Locally Advanced Pancreatic AdenocarcinomaP50CA257881 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Christine A Iacobuzio-Donahue · 2022 to 2026
$14.3M
PROJECT 3: Applying Liquid Biopsy Technologies to Detect Clinical Response and Mechanisms of Resistance in the Treatment of LMSP50CA272170 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Elizabeth Demicco · 2022 to 2026
$13.3M
SPORE in Bladder CancerP50CA221745 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ROSENBERG, JONATHAN ERIC, SOLIT, DAVID B. · 2018 to 2024
$11.8M
Novel therapeutic development for small cell lung cancerR35CA263816 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Charles M. Rudin · 2021 to 2026
$6.3M
Molecular Mechanisms of Drug Resistance in Primary Brain TumorsR35NS105109 · NINDS · SLOAN-KETTERING INST CAN RESEARCH · PI MELLINGHOFF, INGO K · 2018 to 2025
$4.7M
(PQ3) Integrative biomarkers of cancer progression and therapeutic response from germline and somatic clinical sequencingR01CA227534 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BERGER, MICHAEL F. · 2019 to 2023
$3.5M
Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene.R37CA259177 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Christopher Austin Klebanoff · 2021 to 2026
$3.1M
Overcoming Resistance to Targeted Therapy in Breast CancerR35CA305347 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Sarat Chandarlapaty · 2025 to 2026
$2.1M
Novel cell therapy approaches for molecularly defined subsets of therapy-resistant melanomaR01CA286507 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Christopher Austin Klebanoff · 2023 to 2026
$1.8M
MSK Computational Biology Summer ProgramR25CA233208 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Michael F. Berger, Yaihara Myriam Fortis-Santiago · 2019 to 2026
$1.8M
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA221745NCI NIH HHS P50 CA257881NCI NIH HHS P50 CA272170NCI NIH HHS R01 CA227534NCI NIH HHS R01 CA286507NCI NIH HHS R25 CA233208NCI NIH HHS R35 CA263816NCI NIH HHS R35 CA305347NCI NIH HHS R37 CA259177NINDS NIH HHS R35 NS105109
6 · The paper itself

Abstract

The oncogenic impact of somatic driver alterations is shaped by tissue context. Classifying alterations by cancer type and evaluating their context-specific properties requires large cohorts of genomically profiled and clinically annotated tumors. Here, we define cancer type-specific patterns of driver alterations, including 164 newly identified hotspots, in 54,331 tumors from 48,179 patients spanning 448 histological cancer subtypes. One-third of all drivers arose in non-canonical contexts and exhibited distinct features, including increased subclonality, later emergence, and divergent biological properties. Within cancer types, gene fusions and other distinct patterns of co-occurring drivers are indicative of earlier age of disease onset. We also identify ancestry-specific differences in human leukocyte antigen (HLA)-restricted driver neoantigens affecting T cell receptor therapy eligibility, and demonstrate cancer-type-specific patterns of intrinsic resistance via somatic HLA loss. Our findings highlight that functional roles of driver alterations depend on the cancer types and clinical contexts in which they arise.

Indexed as

MutationNeoplasmsHLA AntigensHumansHLA Antigensage of cancer diagnosiscancer type-specificclinical sequencingdriver alterationsHLA genotypeHLA loss of heterozygosityhotspotsneoantigen-directed TCR therapiesprecision oncologytissue-specific

Identifiers

PMID41895280
PMCPMC13198192

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.